FZD7 and neoplasm: Having established that Fzd7-positive cells harbor tumor initiating potential, we reasoned that targeted killing of these cells with a Fzd7-specifc antibody drug conjugate (F7-ADC) composed of F7-Ab conjugated to an antimitotic payload drug, monomethyl auristatin E (MMAE), would lead to tumor growth arrest.